Sugi Predict

Sugi Predict / Compounds / Dynorphin A (1-17)

Dynorphin A (1-17)

Dynorphin A (1-17)

SCHEMBL29358748

CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ OPRD1 P41143 8/20 0.70
▸ F2 P00734 4/20 0.66
▸ NMBR P28336 1/20 0.63
▸ GRPR P30550 1/20 0.63
▸ OPRM1 P35372 1/20 0.62
▸ OPRK1 P41145 1/20 0.62
▸ NTSR1 P30989 2/20 0.62
▸ PCSK9 Q8NBP7 1/20 0.62
▸ NTSR2 O95665 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dynorphin A (1-17) SCHEMBL29599476 1.00 OPRD1 (0.70) OPRD1F2NMBRGRPROPRM1
Dynorphin A (1-17) SCHEMBL30248363 0.94 NPY1R (0.68) OPRD1
Dynorphin A (1-17) SCHEMBL31331988 0.94 NPY1R (0.68) OPRD1
SCHEMBL30589447 0.91 CXCR4 (0.68) OPRD1
SCHEMBL30648474 0.89 NPY1R (0.66) F2
Dynorphin A (1-11) SCHEMBL30132402 0.89 OPRD1 (0.86) OPRD1OPRM1OPRK1NTSR1NTSR2
Analog Of Dynorphin A SCHEMBL29389694 0.89 OPRD1 (0.86) OPRD1OPRM1OPRK1NTSR1NTSR2
SCHEMBL31182657 0.88 NPY1R (0.68) —
SCHEMBL29878209 0.88 OPRD1 (0.85) OPRD1OPRM1OPRK1NTSR1NTSR2
SCHEMBL29491173 0.88 C5AR1 (0.65) OPRD1F2NMBRGRPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186427-A1 METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS UNIVERSITY OF WASHINGTON 2025-06-12 — — US claimed
CN-120079360-A Oily sewage adsorbent and preparation method and application thereof 中国石油化工股份有限公司 2025-06-03 — — CN claimed
WO-2025040658-A1 SELECTIVE CYCLIZED PEPTIDE KAPPA-OPIOID RECEPTOR AGONISTS MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2025-02-27 — — WO claimed
WO-2025040657-A1 SELECTIVE CYCLIZED PEPTIDE KAPPA-OPIOID RECEPTOR ANTAGONISTS MEDIZINISCHE UNIVERSITÄT WIEN (AT) 2025-02-27 — — WO claimed
US-20240269230-A1 CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY MEDIZINISCHE UNIVERSITAT WIEN (AT) 2024-08-15 — — US claimed
US-20240252484-A1 Methods and Compositions for Treating Vasomotor Symptoms UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION 2024-08-01 — — US claimed
CN-115697371-A Macrocyclic oligopeptides in combination with kappa opioid receptor ligands for MS therapy 维也纳医科大学 2023-02-03 — — CN claimed
EP-4121085-A1 CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY Medizinische Universität Wien (AT) 2023-01-25 — — EP claimed
US-20220133839-A1 PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) TXP PHARMA GMBH (CH) 2022-05-05 — — US claimed
US-20220125781-A1 Methods and Compositions for Treating Vasomotor Symptoms UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION 2022-04-28 — — US claimed
US-20220113288-A1 NEUROTRANSMITTER-BASED BRAIN MAPPING METHOD AND USE OF BRAIN MAP NEUROVIS INC. (KR) 2022-04-14 — — US claimed
WO-2022052996-A1 USES OF PROTOPANAXADIOL COMPOUNDS IN TREATMENT OF PAIN, AND PHYSICAL DEPENDENCE, PSYCHOLOGICAL DEPENDENCE AND ADDICTION OF ADDICTIVE SUBSTANCES 上海交通大学 2022-03-17 — — WO claimed
CN-114159450-A Use of protopanoxadiol compounds in treating pain and addiction to substances physical dependence, mental dependence and addiction 上海交通大学 2022-03-11 — — CN claimed
US-20260137810-A1 GENE THERAPY VECTORS FOR THE EXPRESSION OF PREPRODYNORPHIN VARIANTS FOR THE TREATMENT OF EPILEPSY CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) 2026-05-21 — — US disclosed
CN-116472085-B Self-interlocking microstructures 科萨斯生物有限公司 2026-05-15 — — CN disclosed
US-12624002-B2 Dimers for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-05-12 — — US disclosed
CN-114026213-A Continuous blade type impeller 龙沙有限公司 2022-02-08 — — CN disclosed
WO-2022026900-A2 NK RECEPTOR ANTAGONISTS FOR CANCER PATIENTS ACER THERAPEUTICS INC. (US) 2022-02-03 — — WO disclosed
US-11236520-B2 Customizable facility LONZA LTD (CH) 2022-02-01 — — US disclosed
EP-3942014-A1 CONTINUOUS BLADE IMPELLER Lonza Ltd. (CH) 2022-01-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12624002-B2 Dimers for use in synthesis of peptidomimetics GLUL, ARGLU1, ASNS OPRD1 905/4885F2 401/4885NMBR 326/4885
US-20240252484-A1 Methods and Compositions for Treating Vasomotor Symptoms VASP, PDE3A, PDE2A OPRD1 1577/4885F2 870/4885NMBR 953/4885
US-20260137810-A1 GENE THERAPY VECTORS FOR THE EXPRESSION OF PREPRODYNORPHIN VARIANTS FOR THE TREATMENT OF EPILEPSY PREP, NPY1R, PSD OPRD1 196/4885F2 3412/4885NMBR 1883/4885
US-20250186427-A1 METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS VASP, PDE3A, PDE2A OPRD1 1577/4885F2 870/4885NMBR 953/4885
US-20220125781-A1 Methods and Compositions for Treating Vasomotor Symptoms VASP, PDE3A, PDE2A OPRD1 1577/4885F2 870/4885NMBR 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback